Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
On Wednesday, Oppenheimer reiterated its Outperform rating and $36.00 price target for UroGen Pharma (NASDAQ:URGN), following the recent advisory committee meeting that reviewed the company’s product UGN-102. According to InvestingPro data, this target represents significant upside potential from the current price of $3.93, with the stock currently appearing undervalued based on InvestingPro’s Fair Value analysis. The firm’s analyst, Leland Gershell, provided insights into the potential outcomes of the U.S. Food and Drug Administration (FDA) review process for UGN-102, a treatment for recurrent urothelial cancer.
The analyst noted the range of possible scenarios after last week’s advisory committee meeting, which included the best-case scenario of full approval with a broad label for recurrent disease, and the worst-case scenario of receiving a complete response letter requiring additional randomized trials. Intermediate possibilities could involve a narrower approval label or conditional approval with post-marketing trials. The company’s strong financial position, with impressive gross profit margins of 89.68% and a healthy current ratio of 5.65, could provide flexibility during this regulatory process.
The Prescription Drug User Fee Act (PDUFA) date for UGN-102 is approaching, and there is a possibility that any approval could be postponed beyond the expected date of June 13, 2025. Gershell highlighted that the clinical data suggests UGN-102 could be a viable alternative for patients less suited to the current standard-of-care surgery. Despite the uncertainty, the analyst expressed a more optimistic view of UGN-102’s near-term approval prospects than what is currently reflected in the market.
UroGen Pharma’s shares have been under scrutiny as the FDA’s decision date nears, with investors and analysts alike considering the impact of the potential outcomes on the company’s future. The FDA’s review and the subsequent decision will be crucial in determining the availability of UGN-102 for patients and the financial trajectory for UroGen Pharma. With a market capitalization of $181.2 million and four analysts recently revising their earnings estimates upward, detailed analysis and additional insights are available through InvestingPro’s comprehensive research reports, which offer deep-dive analysis of over 1,400 US stocks.
The advisory committee’s role is to provide recommendations to the FDA, which the agency may or may not follow. The committee’s discussions and the FDA’s final decision are highly anticipated by stakeholders, given the potential to change the treatment landscape for recurrent urothelial cancer. UroGen Pharma and its investors are now awaiting the FDA’s decision, which will mark the next significant milestone for the company.
In other recent news, UroGen Pharma reported its Q1 2025 earnings, revealing a revenue of $20.25 million, which fell short of the projected $22.5 million. The company also missed earnings per share (EPS) expectations, reporting -$0.92 compared to the forecast of -$0.79. Meanwhile, UroGen Pharma’s new drug application for UGN-102 faced a divided response from the FDA’s Oncologic Drugs Advisory Committee, with a narrow vote of 4 to 5 against the drug’s benefit-risk profile. This has led Goldman Sachs to significantly lower its price target for UroGen Pharma from $16 to $3, maintaining a Neutral rating.
Despite these challenges, UroGen’s President and CEO, Liz Barrett, expressed optimism about working with the FDA to further review the application. The FDA’s briefing documents had raised concerns about UGN-102’s trial design and efficacy evaluation, which Oppenheimer analyst Leland Gershell noted, while maintaining an Outperform rating and a $36 target on the stock. UroGen Pharma is preparing for the potential launch of UGN-102 in July 2025, with plans to expand its sales force and commercial infrastructure. The FDA’s final decision on UGN-102 is expected by June 13, 2025, under the Prescription Drug User Fee Act (PDUFA) date.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.